Sarborg Applies Quantum Computing and Signature Intelligence Models to Neuropsychiatric Drug Discovery

Sarborg Limited's application of proprietary quantum computing and Signature Intelligence models to neuropsychiatric targets signals a computational approach to early-stage discovery that R&D and regulatory teams will want to evaluate carefully as the platform moves toward potential partnership agreements. CDT Equity Inc. (Nasdaq: CDT), which holds a 22.7% stake in Sarborg, highlighted the development on 10 September 2026.

Sarborg has built a proprietary database of neuropsychiatric disease signatures spanning depression, bipolar disorder, anxiety, and schizophrenia. Its patented models are designed to identify candidate relationships between those disease signatures and therapeutic compounds, a computational screening step that, if validated, could compress early target identification timelines in a therapeutic area where attrition rates remain high and mechanistic complexity is a persistent obstacle to IND-enabling work.

For drug development teams, the immediate question is evidentiary: Sarborg describes successful application of its models but has not, in this announcement, disclosed peer-reviewed data, preclinical outcomes, or regulatory interactions. The platform sits at the intersection of AI-assisted target identification and quantum-enhanced modelling, a combination that carries genuine scientific interest but also requires rigorous prospective validation before it can inform GMP development decisions or regulatory submissions under ICH Q8/Q9 quality-by-design frameworks.

Sarborg is currently in discussions with pharmaceutical and biotechnology companies, academic institutions, and research organisations regarding collaborations. CDT's most recent valuation reference places Sarborg at approximately $709 million fully diluted, based on a capital raise priced at $125,000 per share, a figure that reflects investor appetite for computational drug discovery platforms rather than clinical proof of concept at this stage.

The broader neuropsychiatric context is not incidental: the WHO estimates more than one billion people live with a mental disorder globally, and depression and anxiety alone carry an estimated $1 trillion annual economic burden. Those figures frame the unmet need but do not substitute for the translational evidence that development and regulatory teams will require before committing pipeline resources to any computational platform.

How Sarborg's collaboration discussions progress, and whether partnership terms include milestone-linked validation requirements, will be the measurable checkpoint for R&D leads tracking this platform's trajectory.

Source: CDT Equity Inc. via GlobeNewswire, 10 September 2026.